Voximetry, founded in Madison, WI in 2016, is an early stage healthcare technology company that specializes in commercializing improvements related to nuclear medicine dosimetry. Voximetry’s patient-specific approach can accurately predict efficacy and adverse effects of radiopharmaceutical therapy, thereby improving patient outcomes. Voximetry leverages intellectual property developed at the University of Wisconsin - Madison, which has a rich history of fostering successful biotechnology companies.
10/15/2020 - Voximetry has been awarded a Phase II Small Business Innovation Research (SBIR) grant valued at $1.8 million from the National Cancer Institute (NCI). This award will assist Voximetry in commercializing its Torch software for RPT treatment planning.
Copyright © 2020 Voximetry Inc. - All Rights Reserved.